Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

This approval of Xyrem by the FDA marks the first medicine approved to treat cataplexy or excessive daytime sleepiness in children and adolescents with narcolepsy ages seven and older Efficacy and safety of Xyrem for the treatment of cataplexy or excessive daytime sleepiness in...

from PR Newswire: //https://ift.tt/2Jo6jto